Latest Achillion Pharmaceuticals (ACHN) Headlines
Post# of 94
Posted On: 03/13/2014 4:45:26 AM
Latest Achillion Pharmaceuticals (ACHN) Headlines
Narrower-than-Expected Loss at Achillion, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 8:30AM CDT
The share price of Achillion Pharmaceuticals fell slightly after the company announced its fourth-quarter results.
Achillion Pharmaceuticals ' net loss widens to USD59.0m in 2013
M2 - Mon Mar 10, 7:41AM CDT
US-based biopharmaceutical company Achillion Pharmaceuticals (NasdaqGS :ACHN) announced on Friday a net loss of USD59.0m for the 12 months ended 31 December 2013.
Achillion Reports 2013 Fourth Quarter and Year-End Financial Results
GlobeNewswire - Fri Mar 07, 5:05AM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and twelve months ended December 31, 2013.
Achillion Hasn't Stopped Aching
at The Street - Tue Mar 04, 3:42PM CST
It's a mistake to buy these shares before any real announcement about when the new hepatitis-C drugs will come to market.
5 Stocks Gearing Up for Monster Short Squeezes
at The Street - Fri Feb 28, 7:12AM CST
These heavily shorted stocks could get squeezed higher on any positive catalyst
The 10 Most Heavily Shorted Bio-Pharma Stocks
at The Street - Mon Feb 24, 9:39AM CST
The No. 1 stock on this list has more than half its float short.
Achillion Pharmaceuticals, Inc. (ACHN) Soars: Stock Up 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 7:51AM CST
Achillion Pharmaceuticals, Inc. was a big mover last session, as its shares rose over 10% on the day.
Mattersight Announces Fourth Quarter 2013 Results
Marketwire - Wed Feb 12, 3:44PM CST
Mattersight Corporation (NASDAQ: MATR) today announced financial results for the fourth quarter ended December 31, 2013.
Achillion to Present at Two Upcoming Investor Conferences
GlobeNewswire - Mon Feb 10, 5:00AM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at two upcoming investor conferences:
Nigeria Tops AJC First Leg Qualifiers
by Orkula Shaagee - All Africa Global Media - Fri Jan 17, 3:38AM CST
Team Nigeria was in comfortable lead yesterday as the first leg of the 2014 African Junior Tennis Championship (AJC) qualifiers ended at the Abuja National Stadium yesterday.
Stock Price Movements, FDA Applications, Appointments, and Clinical Study Updates - Research Report on Alere, ARCA, Achillion, Idenix Pharmaceuticals, and Receptos
PR Newswire - Mon Jan 13, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Alere Inc. (NYSE: ALR), ARCA biopharma, Inc. (NASDAQ: ABIO), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), and Receptos, Inc. (NASDAQ: RCPT). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Achillion Reports HCV Pipeline Progress and Outlines 2014 HCV Milestones
GlobeNewswire - Mon Jan 13, 5:25AM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported progress on the Company's portfolio of proprietary compounds for the treatment of chronic hepatitis C (HCV) and outlined its 2014 milestones.
Achillion Pharmaceuticals (ACHN) Surges: Stock Moves 13.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 09, 8:04AM CST
Achillion Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise over 13% on the day.
Patients Enrolled in Synageva Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 07, 3:15PM CST
Synageva finished enrolling patients for its phase III study on sebelipase alfa.
Exelixis (EXEL) Jumps: Stock Moves 11.1% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 07, 8:25AM CST
Exelixis was a big mover last session, with shares rising over 11%.
Athersys (ATHX) in Focus: Stock Moves 6.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 07, 8:04AM CST
Athersys, Inc. was a big mover last session, as the company saw its shares rise by over 6% on the day.
5 Stocks Poised for Breakouts
at The Street - Fri Jan 03, 2:19PM CST
These stocks look ready to break out and trade higher from current levels.
AxoGen (AXGN) in Focus: Stock Surges 25.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 02, 8:46AM CST
AxoGen was a big mover last session, with shares rising over 25%.
Commit To Buy Achillion Pharmaceuticals At $2.50, Earn 24% Using Options
at The Street - Tue Dec 31, 10:08AM CST
Investors considering a purchase of Achillion Pharmaceuticals Inc. stock, but cautious about paying the going market price of $3.31/share, might benefit from considering selling puts among the alternative strategies at their disposal.
3 Most Horrendous Health-Care Stocks of 2013
Keith Speights, The Motley Fool - Motley Fool - Sat Dec 28, 9:00AM CST
Health-care has been hot in 2013. Not every stock in the sector has sizzled, though. Here are three of the most horrendous health-care stocks of the year. A disappointing fish tale Many investors had high hopes early in 2013 for Amarin . Those...
Narrower-than-Expected Loss at Achillion, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 8:30AM CDT
The share price of Achillion Pharmaceuticals fell slightly after the company announced its fourth-quarter results.
Achillion Pharmaceuticals ' net loss widens to USD59.0m in 2013
M2 - Mon Mar 10, 7:41AM CDT
US-based biopharmaceutical company Achillion Pharmaceuticals (NasdaqGS :ACHN) announced on Friday a net loss of USD59.0m for the 12 months ended 31 December 2013.
Achillion Reports 2013 Fourth Quarter and Year-End Financial Results
GlobeNewswire - Fri Mar 07, 5:05AM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and twelve months ended December 31, 2013.
Achillion Hasn't Stopped Aching
at The Street - Tue Mar 04, 3:42PM CST
It's a mistake to buy these shares before any real announcement about when the new hepatitis-C drugs will come to market.
5 Stocks Gearing Up for Monster Short Squeezes
at The Street - Fri Feb 28, 7:12AM CST
These heavily shorted stocks could get squeezed higher on any positive catalyst
The 10 Most Heavily Shorted Bio-Pharma Stocks
at The Street - Mon Feb 24, 9:39AM CST
The No. 1 stock on this list has more than half its float short.
Achillion Pharmaceuticals, Inc. (ACHN) Soars: Stock Up 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 7:51AM CST
Achillion Pharmaceuticals, Inc. was a big mover last session, as its shares rose over 10% on the day.
Mattersight Announces Fourth Quarter 2013 Results
Marketwire - Wed Feb 12, 3:44PM CST
Mattersight Corporation (NASDAQ: MATR) today announced financial results for the fourth quarter ended December 31, 2013.
Achillion to Present at Two Upcoming Investor Conferences
GlobeNewswire - Mon Feb 10, 5:00AM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at two upcoming investor conferences:
Nigeria Tops AJC First Leg Qualifiers
by Orkula Shaagee - All Africa Global Media - Fri Jan 17, 3:38AM CST
Team Nigeria was in comfortable lead yesterday as the first leg of the 2014 African Junior Tennis Championship (AJC) qualifiers ended at the Abuja National Stadium yesterday.
Stock Price Movements, FDA Applications, Appointments, and Clinical Study Updates - Research Report on Alere, ARCA, Achillion, Idenix Pharmaceuticals, and Receptos
PR Newswire - Mon Jan 13, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Alere Inc. (NYSE: ALR), ARCA biopharma, Inc. (NASDAQ: ABIO), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), and Receptos, Inc. (NASDAQ: RCPT). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Achillion Reports HCV Pipeline Progress and Outlines 2014 HCV Milestones
GlobeNewswire - Mon Jan 13, 5:25AM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported progress on the Company's portfolio of proprietary compounds for the treatment of chronic hepatitis C (HCV) and outlined its 2014 milestones.
Achillion Pharmaceuticals (ACHN) Surges: Stock Moves 13.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 09, 8:04AM CST
Achillion Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise over 13% on the day.
Patients Enrolled in Synageva Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 07, 3:15PM CST
Synageva finished enrolling patients for its phase III study on sebelipase alfa.
Exelixis (EXEL) Jumps: Stock Moves 11.1% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 07, 8:25AM CST
Exelixis was a big mover last session, with shares rising over 11%.
Athersys (ATHX) in Focus: Stock Moves 6.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 07, 8:04AM CST
Athersys, Inc. was a big mover last session, as the company saw its shares rise by over 6% on the day.
5 Stocks Poised for Breakouts
at The Street - Fri Jan 03, 2:19PM CST
These stocks look ready to break out and trade higher from current levels.
AxoGen (AXGN) in Focus: Stock Surges 25.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 02, 8:46AM CST
AxoGen was a big mover last session, with shares rising over 25%.
Commit To Buy Achillion Pharmaceuticals At $2.50, Earn 24% Using Options
at The Street - Tue Dec 31, 10:08AM CST
Investors considering a purchase of Achillion Pharmaceuticals Inc. stock, but cautious about paying the going market price of $3.31/share, might benefit from considering selling puts among the alternative strategies at their disposal.
3 Most Horrendous Health-Care Stocks of 2013
Keith Speights, The Motley Fool - Motley Fool - Sat Dec 28, 9:00AM CST
Health-care has been hot in 2013. Not every stock in the sector has sizzled, though. Here are three of the most horrendous health-care stocks of the year. A disappointing fish tale Many investors had high hopes early in 2013 for Amarin . Those...
(0)
(0)Alexion Pharmaceuticals Inc. (ALXN) Stock Research Links
Scroll down for more posts ▼